OBJECTIVE: This study evaluated the relationship between selected acromegaly complications such as IGF-1 serum concentrations at diagnosis as well as of controlled and uncontrolled disease. METHODS: A total of 113 acromegaly patients were enrolled to the study and the duration of active and uncontrolled disease was evaluated as a crucial cause of selected complications. RESULTS: Goiter, diabetes, hypercholesterolemia, hypertriglycerydemia, hypertension and ischemic heart disease were diagnosed in 85(75.2 %), 23(20.3 %), 48(51.0 %), 15(13.3 %), 65(57.5 %) and 18(15.9%) patients, respectively. Prevalence of goiter and diabetes was significantly related to the duration of uncontrolled acromegaly (p<0.01) as well as to the prevalence of hypertension and ischaemic heart disease (p0.05). After three years, there was a significant risk of an acromegaly patient being diagnosed at least with one of the above mentioned diseases (p<0.05) and such risk became more significant after four years (p0.05) related to the prevalence of the already mentioned complications. CONCLUSION: The treatment of acromegaly patients should be geared towards fulfilling all criteria for controlled disease, thereby alleviating potential complications and decreasing mortality.
OBJECTIVE: This study evaluated the relationship between selected acromegaly complications such as IGF-1 serum concentrations at diagnosis as well as of controlled and uncontrolled disease. METHODS: A total of 113 acromegalypatients were enrolled to the study and the duration of active and uncontrolled disease was evaluated as a crucial cause of selected complications. RESULTS:Goiter, diabetes, hypercholesterolemia, hypertriglycerydemia, hypertension and ischemic heart disease were diagnosed in 85(75.2 %), 23(20.3 %), 48(51.0 %), 15(13.3 %), 65(57.5 %) and 18(15.9%) patients, respectively. Prevalence of goiter and diabetes was significantly related to the duration of uncontrolled acromegaly (p<0.01) as well as to the prevalence of hypertension and ischaemic heart disease (p0.05). After three years, there was a significant risk of an acromegalypatient being diagnosed at least with one of the above mentioned diseases (p<0.05) and such risk became more significant after four years (p0.05) related to the prevalence of the already mentioned complications. CONCLUSION: The treatment of acromegalypatients should be geared towards fulfilling all criteria for controlled disease, thereby alleviating potential complications and decreasing mortality.
Authors: F E Keskin; D O Yetkin; H M Ozkaya; O Haliloglu; S Sadri; N Gazioglu; N Tanrıover; H Ak; E Hatipoglu; P Kadıoglu Journal: J Endocrinol Invest Date: 2015-02-26 Impact factor: 4.256
Authors: S Petersenn; M Christ-Crain; M Droste; R Finke; J Flitsch; I Kreitschmann-Andermahr; A Luger; J Schopohl; G Stalla Journal: Internist (Berl) Date: 2017-11 Impact factor: 0.743
Authors: K Wolinski; A Stangierski; K Dyrda; K Nowicka; M Pelka; A Iqbal; A Car; M Lazizi; N Bednarek; A Czarnywojtek; E Gurgul; M Ruchala Journal: J Endocrinol Invest Date: 2016-10-21 Impact factor: 4.256
Authors: M B Antsiferov; V S Pronin; T M Alekseeva; O A Ionova; E Y Martynova; Yu E Poteshkin; N A Chubrova; K Y Zherebchikova Journal: Probl Endokrinol (Mosk) Date: 2021-01-08